Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori : A Multicenter Randomized Non-Inferiority Trial

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Helicobacter pylori (H. pylori) infection is a common global infectious disease of the gastrointestinal tract. Helicobacter pylori eradication can effectively prevent the development of gastric cancer.The researchers collect H.pylori-positive patients who need native therapy. The subjects were randomized to receive7 days and 14 days of bismuth quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates and patient compliance of each group.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• Patients aged 18-70.

• Without active hepatitis.

• Helicobacter pylori infection (either positive for rapid urease test, C13/C14 urea breath test).

• Patients who have not previously received helicobacter pylori eradication therapy.

Locations
Other Locations
China
Department of Gastroenterology, Qilu Hospital, Shandong University
RECRUITING
Jinan
Contact Information
Primary
Yanqing Li, Ph.D
liyanqing@sdu.edu.cn
+8653188369277
Time Frame
Start Date: 2023-09-02
Estimated Completion Date: 2024-08-30
Participants
Target number of participants: 254
Treatments
Experimental: 7 days
Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid
Active_comparator: 14 days
Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid
Related Therapeutic Areas
Sponsors
Collaborators: Zibo Maternal and Child Health Hospital, Linyi Yizhou Hospital, Zaozhuang Municipal Hospital, Jinxiang County People's Hospital, Shandong University of Traditional Chinese Medicine, Yantai Penglai Traditional Chinese Medicine Hospital, Binzhou Maternal and Child Health Hospital
Leads: Shandong University

This content was sourced from clinicaltrials.gov